Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Neutral 0

Zoetis (ZTS) Falls More Steeply Than Broader Market: What Investors Need to Know

AI-generated analysis

📉 Zoetis (ZTS) shares closed down 2.81% at $113.35, underperforming the S&P 500's 1.67% loss and other major market indices.

📉 Over the past month, ZTS shares have declined 10.12%, trailing the broader Medical sector's drop of 7.36% and the S&P 500's 6.15% decline.

📅 Investors are closely watching Zoetis' upcoming earnings release, with consensus EPS estimates projected at $1.61, reflecting an 8.78% year-over-year increase.

💰 Revenue forecasts for the upcoming quarter stand at $2.32 billion, indicating a 4.58% growth compared to the corresponding quarter last year.

🔮 Full-year consensus estimates anticipate earnings of $6.99 per share and revenue of $9.91 billion, both representing modest double-digit growth over the prior year.

⚠️ Analyst forecast revisions can signal future stock performance, with positive changes suggesting optimism regarding business trends and profitability.

🏆 Zoetis currently holds a Zacks Rank of #2 (Buy), having seen a 0.06% rise in its consensus EPS estimate over the past month.

💵 The company trades at a Forward P/E ratio of 16.69, which is lower than the industry average of 17.97, suggesting a potential valuation discount.

📊 Zoetis has a PEG ratio of 1.79, factoring in expected earnings growth, compared to an industry medical drugs average of 1.24.

🏭 The Medical - Drugs industry holds a Zacks Industry Rank of 99, placing it in the top 41% out of all tracked industries.

📈 Historical data indicates that high-performing industries tend to significantly outperform the bottom half by a factor of 2 to 1.

Bullish Signals
  • Zoetis' upcoming quarterly earnings are projected to reach $1.61 per share, representing an 8.78% increase over the same quarter last year.
  • Revenue is forecast at $2.32 billion, which indicates a 4.58% growth compared to the corresponding quarter of the prior year.
  • Full-year Zacks Consensus Estimates suggest earnings of $6.99 per share and revenue of $9.91 billion, both marking positive changes of +9.05% and +4.66% respectively from last year.
  • The Zacks Rank for Zoetis is #2 (Buy), with #1 ranked stocks delivering an average annual return of +25% since 1988.
  • Zoetis is currently trading at a Forward P/E ratio of 16.69, which is below the industry average Forward P/E of 17.97, suggesting a valuation discount.
  • The Medical - Drugs industry has a Zacks Industry Rank of 99, placing it in the top 41% of all 250+ industries, indicating strong relative performance potential.
Risk Factors
  • Zoetis stock price fell -2.81% recently, outperforming the market decline more negatively as it underperformed the S&P 500 (down 1.67%) and Nasdaq (down 2.15%).
  • Shares had already lost 10.12% in the past month compared to only a 6.15% drop for the broader S&P 500, indicating relative weakness.
  • The PEG ratio of 1.79 is significantly higher than the industry average of 1.24, potentially suggesting overvaluation relative to its expected earnings growth.
  • Zoetis trades at a Forward P/E of 16.69 which is slightly lower than the industry average of 17.97, but investors should remain cautious given recent momentum.
Full Analysis
Zoetis Inc. (ZTS) shares closed lower at $113.35, marking a 2.81% decline for the day and outpacing the broader market's negative momentum, which saw the S&P 500 drop 1.67%, the Dow fall 1.73%, and the Nasdaq lose 2.15%. Over the past month, ZTS stock had already underperformed by 10.12%, compared to a 7.36% loss for the Medical sector and a 6.15% loss for the S&P 500. Investors are now closely watching the company's upcoming earnings release, which has generated significant interest following this recent price weakness. Analyst expectations for Zoetis remain positive despite the stock's short-term downturn, with projected quarterly earnings of $1.61 per share, representing an 8.78% increase year-over-year. Revenue is forecasted to reach $2.32 billion, indicating a 4.58% growth compared to the prior quarter's figures. Full-year estimates from Zacks Consensus suggest earnings of $6.99 per share and revenue of $9.91 billion, reflecting projected changes of +9.05% and +4.66% respectively from last year. Recent revisions to these analyst forecasts are being monitored closely as they often correlate with impending stock price performance according to empirical research. Valuation metrics indicate Zoetis is trading at a Forward P/E ratio of 16.69, which suggests a discount compared to the industry average of 17.97. The company also has a PEG ratio of 1.79, whereas the Medical - Drugs industry average stands at 1.24. Industry analysis places Zoetis within a sector ranked in the top 41% of all industries by the Zacks Industry Rank system, which assesses group vigor based on individual stock rankings and shows that top-rated industries outperform the bottom half by a factor of 2 to 1. Currently, Zoetis holds a Zacks Rank of #2 (Buy), while its Consensus EPS estimate has seen a slight rise of 0.06% over the past month. Historically, the Zacks Rank system from Zacks Investment Research has delivered strong performance, with #1 stocks posting an average annual return of +25% since 1988 based on outside-audited data. The article concludes by directing investors to monitor stock-impacting metrics such as analyst revisions and industry ranks via Zacks.com and offers a downloadable report of top picks for the next 30 days.